NCT06009237View on ClinicalTrials.gov

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

ABBV-903

Tablet; oral

DRUG

Placebo for ABBV-903

Tablet; oral

Trial Locations (1)

92801-2658

Anaheim Clinical Trials LLC /ID# 257033, Anaheim

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY